We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2006 by Sheba Medical Center.
Recruitment status was:  Not yet recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00339118
First Posted: June 20, 2006
Last Update Posted: June 20, 2006
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Sheba Medical Center
June 19, 2006
June 20, 2006
June 20, 2006
Not Provided
Not Provided
  • event free survival
  • overall survival
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children
Not Provided
The purpose of the study is achieve standardization treatment of low and intermediate risk rhabdomyosarcoma patients, with an attempt to improve treatment results in high and very high risk patients by the addition of doxorubicin as induction treatment and at the maintenance phase.
Not Provided
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Rhabdomyosarcoma
Drug: doxorubicin, cytoxan
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • child
  • non metastatic rhabdomyosarcoma
  • adequate heart, kidney, liver function

Exclusion Criteria:

  • age over 21 years, under 6 months
  • metastatic disease
  • heart, kidney, liver disease
Sexes Eligible for Study: All
6 Months to 21 Years   (Child, Adult)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00339118
SHEBA-06-4013-IK-CTIL
Not Provided
Not Provided
Not Provided
Not Provided
Sheba Medical Center
Not Provided
Principal Investigator: Iris Kventsel, MD Sheba Medical Center
Sheba Medical Center
June 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP